Author:
Barash Mark,Reich Keith A.,Rademaker Dennis
Abstract
Abstract
Methemoglobinemia is a rare condition in which the iron in hemoglobin is stabilized in the ferric (Fe3+) form, making it unable to bind oxygen and leading to tissue hypoxia and possibly death. The condition may be hereditary or acquired, the latter resulting from ingestion or application of common oxidizing agents such as lidocaine. As management of methemoglobinemia depends on prompt recognition, clinicians who administer or prescribe oxidizing agents must be aware of the clinical symptoms of methemoglobinemia, including cyanosis, pulse oximetry values that do not respond to increased oxygen delivery, and altered mental status. Currently, methylene blue is the drug of choice for the management of methemoglobinemia.
Subject
Complementary and alternative medicine,Complementary and Manual Therapy
Reference27 articles.
1. Methemoglobinemia: pathogenesis, diagnosis, and management;Skold;South Med J.,2011
2. Methemoglobinemia: etiology, pharmacology, and clinical management;Wright;Ann Emerg Med.,1999
3. Methemoglobinemia as a cause of coma;Caudill;Ann Emerg Med.,1990
4. Assessment of severity of methaemoglobinemia following fibreoptic bronchoscopy with lidocaine;De;Indian J Chest Dis Allied Sci.,2011
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献